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Abstract
Dengue virus (DENV) is a major mosquito-borne pathogen infecting up to 100 million people each year; so far no effective
treatment or vaccines are available. Recently, highly cross-reactive and infection-enhancing pre-membrane (prM)-specific
antibodies were found to dominate the anti-DENV immune response in humans, raising concern over vaccine candidates
that contain native dengue prM sequences. In this study, we have isolated a broadly cross-reactive prM-specific antibody,
D29, during a screen with a non-immunized human Fab-phage library against the four serotypes of DENV. The antibody is
capable of restoring the infectivity of virtually non-infectious immature DENV (imDENV) in FccR-bearing K562 cells.
Remarkably, D29 also cross-reacted with a cryptic epitope on the envelope (E) protein located to the DI/DII junction as
evidenced by site-directed mutagenesis. This cryptic epitope, while inaccessible to antibody binding in a native virus
particle, may become exposed if E is not properly folded. These findings suggest that generation of anti-prM antibodies that
enhance DENV infection may not be completely avoided even with immunization strategies employing E protein alone or
subunits of E proteins.
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Introduction
Dengue virus (DENV) is a flavivirus with four related but
antigenicallydistinctserotypes(DENV1-4).Itinfectsapproximately
50–100millionpeopleeachyear,ofwhich500,000peopleexhibitthe
life-threateningformofseveredengue–denguehaemorrhagicfever
(DHF) and dengue shock syndrome (DSS) [1]. The current lack of
treatment or licensed vaccine means dengue poses a serious public
healththreat[2].InfectionbyoneserotypeofDENVconferslifelong
immunity against the homologous serotype, but only limited cross-
protection to the remaining three serotypes [3,4]. The presence of
cross-reactive, non-neutralizing antibodies generated during a
primary infection has been suggested to enhance the pathogenicity
of subsequent infections via the process of antibody-dependent
enhancement (ADE) [5]. A successful and safe vaccine candidate
mustthereforeelicitaprotectivelong-lastingimmuneresponsetoall
four serotypes [4,6–8].
Recentimmunologicalstudieshaveshownthehumananti-DENV
immuneresponsetobedominatedbyprM-specificantibodiesinboth
primary and secondary infections [9,10]. These prM-specific
antibodies are highly cross-reactive and non-neutralizing. When
complexed with immature DENV (imDENV), it has the ability to
render normally non-infectious imDENV highly infectious [11,12].
Thishascausedconcernovercurrentvaccinecandidatesthatcontain
native dengue prM [9] – which is a component of most current
vaccine strategies whether naturally attenuated, recombinantly
attenuated, yellow fever-dengue-virus chimeras, chemically inacti-
vated virus, DNA vaccine or recombinant subunit protein vaccines
[13,14].VaccinecandidatesthatdonotcontainprMproteins,suchas
soluble recombinant Envelope (E) protein or E domain subunit
vaccines may thus become increasingly important.
To gain a deeper understanding of the early DENV-specific
immune response in humans, the four serotypes of DENV were
sequentially screened with a non-immunized human Fab phage
display library. Broadly cross-reactive prM-specific antibodies
dominated the screen and the Fab with highest affinity, D29 Fab-
IgG,wasconvertedintofull-lengthhumanIgG1formatforthorough
characterization. This antibody (D29 Fab-IgG) was found to have
highaffinityforaconformationalepitopeonprMand,likeotherprM
antibodies[11,12],wascapableofrestoringtheinfectivityofvirtually
non-infectiousimmatureDENV(imDENV)inFccR-bearingK562
cells.Theantibodyalsocross-reactedwithEprotein–finemapping
andsite-directedmutagenesisstudieslocalizedtheepitopetotheDI/
DII junction of E, which would be inaccessible in a native virus
particle. This suggests the possibility that immunization strategies
employingEproteinaloneorsubunitsofEproteinsmaynotbeableto
completely avoid generation of anti-prM antibodies that enhance
DENV infection.
Materials and Methods
Cells
Aedes albopictus C6/36 cells (ATCC) were maintained in
Leibovitz L-15 media (GIBCO, Invitrogen) supplemented with
PLoS ONE | www.plosone.org 1 April 2012 | Volume 7 | Issue 4 | e334518% fetal bovine serum (FBS), at 28
oC, 5% CO2. BHK-21 cells
(ATCC) and human erythroleukemic K562 cells (ATCC) were
maintained in RPMI 1640 GlutaMAX medium (RPMI) (GIBCO,
Invitrogen) containing 10% FBS, and incubated at 37
oC, 5%
CO2. Vero cells (ATCC) were grown in 199 medium (M199)
(GIBCO, Invitrogen) supplemented with 8% FBS, 1% sodium
pyruvate and 1% NEAA. HEK293 T cells (ATCC) was cultured
in Dulbecco’s modified Eagle’s medium (DMEM) (GIBCO,
Invitrogen) supplemented with 10% FBS at 37
oCi n5 %C O 2.
Antibodies and Proteins
Mouse monoclonal antibodies 3H5 (m3H5), 4G2 (m4G2) and
2H2 (m2H2) are specific to EDIII of DENV2, EDII of
flaviviruses and prM of DENV1-4 respectively. Chimeric
humanized 3H5 (h3H5) and 4G2 (h4G2) were constructed by
cloning the Fab portion (variable light and heavy chains) into an
expression vector containing the human IgG1 framework for
expression in HEK293 T cells [15]. Conjugation of HRP to
antibodies-D29, -m3H5 and -m2H2, was performed using the
Lightning-Link HRP Conjugation Kit (Innova Biosciences).
Virus Growth
Dengue 1 (DENV1) strain Hawaii, Dengue 2 (DENV2) strains
New Guinea C (NGC) and ST, Dengue 3 (DENV3) strain H87
and Dengue 4 (DENV4) strain H241 were passaged in Vero cells
for all assays unless otherwise stated. Virus titers were determined
by plaque assay on BHK cells. Immature DENV (imDENV) was
produced as described previously [16]. Briefly, the media of
infected Vero cells was replaced 2 dpi with M199 NH4Cl medium
(M199 with 10% FBS, 1% sodium pyruvate, 1% non essential
amino acids, 1% PS, 2.5 mM L-Glutathione and 20 mM NH4Cl).
Culture supernatants were harvested after 5 days and imDENV
was purified by PEG precipitation. Virus titer was determined as
genome containing particles (GCP)/ml by quantifying real-time
PCR (qPCR) described previously [17].
Direct Binding ELISA
To ascertain the binding specificity of D29 Fab-IgG, direct
binding ELISA against dengue virus was performed using
standard ELISA methods. Briefly, 2610
5 pfu/well purified
DENV1-4 was coated on Maxisorb plate followed by blocking
using 5% SM. Following incubation with 1 mg/ml dengue-specific
antibodies, plates were probed with HRP-conjugated anti-human
IgG-Fc secondary antibody or anti-mouse IgG-Fc secondary
antibody (Pierce). Detection steps in subsequent ELISAs followed
this method unless otherwise stated. To determine the binding
affinity of D29 Fab-IgG direct binding ELISA was performed with
serially diluted D29 Fab-IgG. Results were fitted to a one-site
binding hyperbola using Prism 5.03 (GraphPad, San Diego, USA).
For Peptide phage ELISA, 2 mg of D29 and non-related control
antibodies were coated on Maxisorb plate and incubated with
phage, followed by detection with HRP-conjugated anti-M13
secondary antibody.
Indirect Immunofluorescent Assay (IFA)
DENV-infected Vero cells or C6/36 cells were fixed and
permeablilized with 80% acetone at 220
oC for 10 min. The
presence of virus was detected by D29 Fab-IgG, h3H5 and h4G2
at 1 mg/ml, followed by staining with FITC-conjugated anti-
human IgG (ZyMax, Invitrogen). Cells were mounted with
MOWIOL (Sigma) and images were captured using a fluorescent
microscope (Olympus).
Preparation of Dengue lysate and Western Blot
DENV-infected Vero cells were harvested 5 days post-infection
and lysed with cold lysis buffer (1.5% Triton X-100, 0.2 mM
Phenylmethylsulfonyl Fluoride (PMSF), 1 mg/ml pepstatin A and
75 mM KCl in PBS) for 40 min on ice. An equal volume of 56
loading dye was added to the cell lysate before 12% SDS-PAGE
and transferred onto nitrocellulose membranes. Blocked mem-
branes were probed with dengue-specific antibodies at RT for 1 hr
and detected with HRP-conjugated anti-human IgG-Fc or anti-
mouse IgG-Fc secondary antibody and developed with chemilu-
minescence (Supersignal West Pico Chemiluminescent Substrate,
Pierce).
Competition ELISA and Western Blot
To establish the binding target of D29 Fab-IgG, competition
ELISA against epitope-characterized monoclonal antibodies was
carried out. Plates were prepared as for direct binding ELISA.
After blocking, serially diluted m3H5, m4G2 or m2H2 was added
to the plates and incubated for 1 hr at RT, followed by addition of
D29 Fab-IgG at 2.5 mg/ml and incubation for 1 hr at RT. Bound
antigen-antibody complexes were detected by HRP-conjugated
anti-human IgG-Fc secondary antibody (Pierce), and developed as
described above.
For competition Western, Fab-IgG D29 was incubated with
m3H5, m4G2 or m2H2 for 1 hr at RT before applying to blocked
membranes for 30 min at RT. HRP-conjugated anti-Human IgG-
Fc secondary antibody was applied to detect bound D29 for
45 min at RT after 4 washes with PBST.
Immunoprecipitation
For radioactive immunoprecipitation, DENV2- infected BHK-
21 cells were harvested 48 hr later and prepared as described
previously [18]. For immunoprecipitation with SDS to disrupt
protein complexes, lysate from infected cells was incubated with
1.25% SDS for 30 min at 4
oC. The SDS concentration was
diluted to 0.2% before immunoprecipitation and precipitated
proteins were analysed by silver stained SDS-PAGE (Silver stain
Plus Kit, Bio-Rad) and Western blot.
Phage-displayed Random Peptide Library
The phage-displayed-12 random dodecapeptide (Ph.D-12)
library (New England Biolabs) was panned against D29-Fab-IgG
to identify the antibody epitope as per instruction manual. The
first round of panning was carried out with 100 mg/ml D29 Fab-
IgG immobilized on Maxisorb Immunotube (Nunc). The
amplified phage was enriched by three further rounds of panning
in solution using Protein A or G sepharose in alternate rounds of
panning. One round of negative selection with Protein A and G
sepharose was carried out to minimize non-specific binders. The
isolated peptide phage sequences were mapped against 3D protein
structure using the Peptiope server with crystal structures of prM-
E heterodimer at neutral pH (Protein Data Bank (PDB) accession
code 3C6E). Graphic visualization was carried out using MSI
WebLab ViewLite (Accelrys).
To test whether isolated peptide phage inhibits binding of D29
to its natural epitope, inhibition ELISA was carried out. 10-fold
serially diluted peptide phage (starting at 10
12 pfu/ml) or
2610
5 pfu DENV2 was incubated with D29 Fab-IgG for 1 hr
before applying to DENV2-coated plate for 5 min at RT. Bound
antibody was detected with HRP-conjugated anti-human IgG-Fc
secondary antibody for 1 hr at RT.
To test the inhibition capacity of peptide phage by Western blot,
pre-incubation of 0.1 mg/ml of D29 Fab-IgG with 4610
11 pfu
Human PrM/E Binding Antibody
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6 pfu DENV2 or 5%SM for 1 hr was carried
out before applying to membrane transblotted with DENV2 lysate
for 30 min. HRP-conjugated anti-Human IgG-Fc secondary
antibody was applied to detect bound D29 Fab-IgG for 45 min
at RT and the membrane was processed as described previously to
visualize the reactive bands.
Site-directed Mutagenesis
The gene portion containing prM-E, as described in Puttikhunt, et
al [24], was amplified from DENV2 (NGC) cDNA using the
primers D2-FW (59-AATTAATACGACCGTCTCCCATGAA-
TAGAAGACGCAGATCTGCAGGC-39) and D2-RV (59-CGC-
CCGTTTGATCTCGAGCTACTAGGCCTGCACCATGACT-
CCC-39) and cloned into pCMV-myc-ER vector via the restriction
Figure 1. Binding specificity and affinity of D29 Fab-IgG. To determine the binding specificity of D29 Fab-IgG in a sandwich ELISA format,
DENV2 in infected (A) Vero or (B) C6/36 cell culture media was captured by immobilized m4G2 and detected by 1 mg/ml D29 Fab-IgG, h3H5 and
h4G2. (C) Immunoreactivity of D29 Fab-IgG was also tested in the IFA format against DENV1-4 infected Vero (Ve) or C6/36 (C6) cells. Binding of D29
Fab-IgG was detected by anti-human-IgG-FITC. Non-infected cells (CC) were included as control. (D) To determine its binding affinity, DENV1-4 was
detected by serially-diluted D29 Fab-IgG in a direct binding ELISA format. Values displayed are the average of three independent experiments with
error bars representing the standard errors of the mean. Results were fitted to a one-site binding hyperbola using GraphPad Prism 5.03 (GraphPad,
San Diego, USA) to determine the Kd values for each DENV serotype. (E) Summary of the Kd and R
2 values of D29 Fab-IgG for each DENV serotype.
doi:10.1371/journal.pone.0033451.g001
Human PrM/E Binding Antibody
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E. Using this as template, selected amino acids residues of the
predicted epitopes, P3 and P9, were mutated by site-directed
mutagenesis using Quikchange Multi Site-directed Mutagenesis
kit (Stratagene, Agilent Technologies). PCR reactions and
subsequent cloning steps were carried out according to
manufacturer’s instructions. Substitution of amino acids in all
mutant constructs was confirmed by sequencing. Mutants were
expressed in HEK293-T cells and harvested 48 hr post-
transfection for immunoblot analysis and immunoprecipitation
experiments.
Plaque Reduction Neutralization Test (PRNT) and ADE
Assay
To determine the ability of D29 Fab-IgG to neutralize Dengue
infection in vitro, PRNT was carried out on BHK cells as described
previously [19].
The ADE assay was performed as described previously [20].
Briefly, pre-formed immune complexes were prepared by
incubating serially diluted antibody with DENV2 or imDENV2
at a multiplicity of 25 GCP per cell (MOG 25) in RPMI MM at
37
oC for 1 hr before applying to 2610
4 K562 cells in 96-well U-
bottom plate (Nunc). Supernatant was harvested 48 hr post-
infection and virus titer was quantified by plaque assay.
Results
Binding Specificity and Affinity of D29 Fab-IgG
Following isolation from the human non-immune Fab-phage
library by panning against the 4 serotypes of DENV sequentially
(Fig. S1), D29 Fab-IgG was converted into full length human IgG1
(Materials and Methods S1). To ensure the antibody was specific
for DENV viral proteins, ELISA and IFA were performed with all
4 serotypes of DENV grown in C6/36 and Vero cell lines. D29
Fab-IgG reacted with infected cells from DENV1-4 without cross-
reaction to the non-infected cell controls, indicating that the
determinant for D29 Fab binding is indeed viral and not host
(Fig. 1A, B, C).
Using direct ELISA, D29 Fab-IgG was found to have high
affinity for all 4 serotypes of DENV (Fig. 1D and E):
DENV2(8.69610
211 M),DENV1(9.05610
211 M).DENV4(1.086
10
210 M),DENV3(1.14610
210 M ) .H o w e v e r ,t h ea m i n oa c i d
sequence of its CDRs was found to have little deviation from germline
(Fig. S2), indicating D29 has not been affinity matured via somatic
Figure 2. Competition Assays and Western Blots of D29 Fab-IgG and monoclonal anti-DENV antibodies with known epitope. (A)
Serially diluted h3H5, h4G2 or m2H2 was incubated with immobilized DENV2 (2610
7 pfu/ml) for 1 hr at RT before addition of 2.5 mg/ml of D29 Fab-
IgG for a further hour at RT. Bound D29 Fab-IgG was detected by HRP-conjugated anti-human IgG-Fc antibody. 2.5 mg/ml of HRP-conjugated m2H2
was used to compete against m2H2. Values displayed are the average of three independent experiments and error bars represent standard errors of
the mean. For Western Blot analysis, DENV1-4 (D1-D4) infected Vero cell lysate and 0.5 mg of recombinant DENV2 E protein (ecto-domain) (rE) were
separated on 12% SDS-PAGE in (B) non-reducing, (C) reducing conditions; followed by detection with 1 mg/ml of h3H5, h4G2, m2H2 and D29 Fab-IgG.
(D) For competition Western blot analysis, 0.5 mg/ml of D29 Fab-IgG was incubated with 1 mg/ml of h4G2, h3H5, m2H2 for 1 hr at RT before applying
to membrane transblotted with DENV2 viral lysate for 30 min at RT.
doi:10.1371/journal.pone.0033451.g002
Human PrM/E Binding Antibody
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generated in the early immune response against DENV.
Identification of the Binding Target of D29-Fab IgG
To broadly characterize the epitope of D29 Fab-IgG on DENV,
we used competition ELISA with well characterized DENV
antibodies including mouse-derived 3H5 (m3H5) which is specific
to DENV2 EDIII; m4G2, a cross-reactive antibody that
recognizes EDII of all flaviviruses and m2H2, a cross-DENV
reactive anti-prM antibody [21,22]. Making use of humanized
versus parental murine antibodies for 3H5 and 4G2, and HRP-
conjugated m2H2 versus non-conjugated for m2H2, each of the
reference antibodies was shown to self-compete (Fig. 2A). No
significant competition was observed between D29 Fab-IgG and
m3H5, m4G2 or non-DENV specific control antibody. However,
binding of D29 Fab-IgG to DENV2 decreased significantly in the
presence of m2H2 in a dose-dependent manner, indicating that
D29 Fab-IgG recognized an epitope on prM similar to that of
m2H2 (Fig. 2A).
To confirm the target protein of D29 Fab-IgG, Western blot
analysis was carried out with DENV-infected Vero cell lysates and
the recombinant ectodomain of DENV2 E protein (rE) under
reducing and non-reducing conditions. Under non-reducing
conditions, the control antibodies recognized their respective
target proteins from the cell lysates: h4G2 detected the ,55 kDa E
protein of all 4 serotypes and the ,50 kDa rE protein, and m2H2
detected the ,20 kDa prM of all 4 serotypes (Fig. 2B).
Remarkably, D29 Fab-IgG detected both E and prM of all 4
serotypes; however, the binding was abolished in the presence of
reducing agent, indicating that the D29 epitope is conformational.
All control antibodies except h3H5 lost binding to their target
proteins under reducing condition (Fig. 2C), which is expected
since h3H5 recognizes a linear epitope on EDIII [22,23], whereas
both h4G2 and m2H2 are conformationally sensitive [10,24]. In
agreement with the competition ELISA data, h3H5 and h4G2 did
not compete with D29 Fab-IgG for epitopes in the Western blot
format, whereas incubation with m2H2 abolished D29 binding to
prM but not to E protein (Fig. 2D).
Given the ability of D29 Fab-IgG to bind both prM and E on
western blots, immunoprecipitation was carried out with DENV2-
infected BHK cell lysate to elucidate if D29 Fab-IgG binds both
proteins in solution. An initial radioactive immunoprecipitation
showed D29 Fab-IgG binding to both E (,55 kDa) and prM
(,20 kDa), as both proteins are precipitated whereas h4G2 only
precipitated E protein (Fig. 3A). However, as prM intrinsically
interacts with E to form heterodimers, it is possible that antibody
binding to one of the components in the heterodimer would pull
down the other. To address this, dissociation of the heterodimer
with 1.25% SDS was performed prior to the assay. Immunopre-
cipitated proteins were resolved by reducing SDS-PAGE and
visualized by silver staining. Identity of the precipitated proteins
was verified by non-reducing Western blot analysis with h3H5 and
m2H2, respectively (Fig. 3B). The control antibodies were able to
precipitate their corresponding binding partners. Despite the
ability to recognize both prM and E on western blots, D29 Fab-
IgG only precipitated prM. Taken collectively, our data indicate
that D29 binds both prM and E but the epitope on E is not
accessible on the native protein.
Fine Epitope Mapping by Phage-displayed Random
Peptide Library Screening
As the DTT-sensitive m2H2 had previously been mapped to its
epitope using linear peptides [21], we attempted a similar
approach to locate the binding epitope of D29 Fab-IgG. An
inhibition ELISA was carried out using synthetic ,20 mer linear
Figure 3. Immunoprecipitation of DENV2 proteins with anti-
DENV antibodies. (A) For immunoprecipitation in native condition,
DENV2-infected BHK cells were incubated with media supplemented
with 250 mCi/ml
35S-methionine before lysis. Viral proteins were
precipitated with D29 Fab-IgG or h4G2. (B) For immunoprecipitation
with 1.25% SDS, cleared lysate of DENV2-infected BHK cells were
incubated with h3H5, h4G2, m2H2, D29 Fab-IgG or non-DENV specific
human antibody (IgG) followed by analysis with silver staining and
Western blotting. Precipitated prM and E proteins were verified by (anti-
prM) HRP-conjugated m2H2 or (anti-E) h3H5 respectively. HC - antibody
heavy chain; LC - antibody light chain.
doi:10.1371/journal.pone.0033451.g003
Table 1. Amino acid sequence analysis of selected peptide-
phages screened against D29 Fab-IgG.
Clones selected Sequence Cluster
P1 WSVKLPVWPINH 1
GWPGKLPLWNWD 1
P2 YKQPLWPNWNKL 1
P3 YKQPLWPNQISW 1
P4 KPADVGELGKLY 1
YKLPPLGWQWDG 1
MPPMKPPLWPLE 1
P8 AKTMPWDLLFLL 2
AKTMPGTYYSYW 2
P5 WTLKLPQWLNST 2
WTLKMPWWSSSL 2
WSVKLPVWINHG 2
P9 KEPPDLAWLTRW 2
GSSKVPMWLEW 2
P6 NHQHKIPLWNSW 3
P7 KLPMWENWANYT 3
TMKQPPRQWHFW /
SSTTYHSVISG /
QKLPPMGHLLFG /
doi:10.1371/journal.pone.0033451.t001
Human PrM/E Binding Antibody
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15-mer overlapping linear peptides (Mimotope) corresponding to
aa1–166 of prM and aa1–495 of E (Materials and Methods S1).
However, none of the linear peptides were able to significantly
inhibit the binding of D29 Fab-IgG to DENV2 (Fig. S3),
suggesting that the epitope of D29 Fab-IgG1 is discontinuous.
Next, D29 Fab-IgG was screened using a random dodecapep-
tide (Ph.D-12)-phage library as this approach has previously been
used to map antibody-binding motifs [26,27]. Peptide-phage
clones were randomly selected from the second, third and fourth
round of panning, and their binding specificity was confirmed by
direct binding ELISA against D29 Fab-IgG. Reactive clones were
sequenced and checked against a list of common target-unrelated
peptides (TUPs) [28] to eliminate peptides that react with constant
regions of antibodies, protein A/G sepharose or plastic surfaces.
No TUPs were detected and the resulting 20 unique clones fall
into three main consensus groups: 26% contained the motif
W(TL/SV)K(L/X)PXW; 14% contained the motif AKTMP and
33% contained the motif KXPXW (Table 1).
Mapping of peptide sequences using the Peptiope server against
the 3D crystal structure of the prM-E heterodimer at neutral pH
(PDB 3C6E) identified three main clusters of predicted epitope
location. Since Pepitope assumes all input peptides mimic surface
residues; all buried residues are eliminated from the search. The
Figure 4. Localization of D29 Fab-IgG predicted epitopes in 3D crystal structures of DENV2 prM-E heterodimer (PDB 3C6E) and the
binding specificity of peptide-phages. (A) Clusters of conformational epitopes predicted by Pepitope server are displayed on the prM-E
heterodimer crystal structure at neutral pH with their solvent-accessible surfaces highlighted. The prM is pink, EDI is red, EDII is yellow, EDIII is blue, FP
is cyan. (B) The binding specificity of peptide-phages (P1-P9) to D29 Fab-IgG was tested in a direct ELISA format with 10 mg/ml of D29 Fab-IgG, h3H5,
m2H2 and non-DENV specific human antibody (Hu) immobilized on a Maxisorb plate. Ability of peptide-phages to inhibit D29 Fab-IgG binding to
DENV2 was investigated by (C) ELISA and (D) Western blot analysis. For ELISA, peptide-phages (10
12 pfu/ml) were incubated with D29 Fab-IgG for
1 hr at RT before application to immobilized DENV2 for 5 min at RT. Bound D29 Fab-IgG was detected with HRP-conjugated anti-Human IgG-Fc. The
percentage of inhibition of D29 Fab-IgG binding by the peptide-phages shown is the average of three experiments. Error bars represent the standard
errors of the mean (***p-value ,0.005). For Western blot analysis, 0.5 mg/ml of D29 Fab-IgG was incubated with 8610
6 pfu of purified DENV2, 5% SM
or 4610
11 pfu of peptide-phage clones for 1 hr at RT before applying to membrane transblotted with DENV2 viral lysate for 30 min at RT.
doi:10.1371/journal.pone.0033451.g004
Human PrM/E Binding Antibody
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highest scoring Cluster 1 located at the prM/EDII interface. A few
exceptions mapped to Cluster 3, most probably due to poorer
sequence match and a lower alignment score. The remaining two
motifs were mapped to the second highest scoring Cluster 2 that
spans EDI and EDII (Fig. 4A).
To verify the specificity of the identified motifs, nine
representative clones were selected (Table 1) and assessed for
their ability to bind D29 Fab-IgG by direct ELISA. No cross-
reaction by these peptide-phage clones with control antibodies was
observed, confirming that the binding to D29 Fab-IgG was specific
(Fig. 4B). The peptide-phage clones were then tested for their
ability to inhibit D29 Fab-IgG’s binding to immobilized DENV2.
Although most of the selected peptide-phage clones only weakly
inhibited D29 Fab-IgG’s binding to DENV2, clone P3 (Cluster 1)
and P9 (Cluster 2) significantly competed by 30% and 70%,
respectively (Fig. 4C). Significant inhibition of binding to both
prM and E was also observed on Western blot for P9, however no
noticeable inhibition was observed for P3 (Fig. 4D). Alignment of
P3 and P9 peptide sequences to their respective clusters revealed 9
and 11 aa match, respectively (Fig. 5). This may explain the
difference in the ability of the two peptide phage clones to inhibit
binding of D29 Fab-IgG.
Site-directed Mutagenesis
To confirm the residue assignation of the predicted epitopes for
D29 on prM and E, clusters of 2–3 residue mutants were made on
a prM-E construct that Puttikhunt and co-workers had previously
shown to fold correctly when expressed in HEK293 [24] For the
P3 (prM-E) epitope, two mutants, M1 (P56L-A, P58Q-G, P59N-
G) and M2 (E246K-A, E247K-A) were generated (Fig. 6A). Their
reactivity with D29 Fab-IgG was tested by Western blot analysis,
using h4G2 and m2H2 as control antibodies. All antibodies
reacted with their respective protein targets for the non-mutated
prM-E protein; however, binding of m2H2 and D29 Fab-IgG to
the prM protein was almost completely abolished by mutation at
the prM residues in M1 (Fig. 6B). Mutation at the E residues
within the P3 sequence (M2) on the other hand, did not have
significant impact on the reactivity with D29 Fab-IgG (Fig. 6B).
Detection of both M1 and M2 by h4G2 verified the expression of
both mutants. To verify the P9 (E) epitope, eight mutants were
generated: M3 (E55T-A), M4 (E56L-A, E57R-G), M5 (E129V-A,
E131Q-G), M6 (E133E-G, E134N-G), M3/4 (E55T-A, E56L-A,
E57R-G), M3/5 (E55T-A, E129V-A, E131Q-G), M4/5 (E56L-A,
E57R-G, E129V-A, E131Q-G) and M5/6 (E129V-A, E131Q-G,
E133E-G, E134N-G) (Fig. 6A). Both control antibodies were able
detect their respective protein targets for all mutants, apart from
Figure 5. Localization of P3 and P9 peptide sequence on 3D crystal structure of prM-E heterodimer (PDB 3C6E). P3 (Purple) and P9
(green) peptide sequences were aligned with the predicted clusters (Cluster 1 – Navy blue; Cluster 2 – Black) on the prM-E crystal structure. The path
of peptide phage sequences was highlighted with the participating residues from the cluster and the peptide phage labeled. Matched residues were
purple (P3) or green (P9) and numbered accordingly; mis-matched residues were grey. The respective proteins and domains were highlighted as
above.
doi:10.1371/journal.pone.0033451.g005
Human PrM/E Binding Antibody
PLoS ONE | www.plosone.org 7 April 2012 | Volume 7 | Issue 4 | e33451M3/4 and M4/5 which appeared to be non-viable (Fig. 6B). The
binding of h4G2 to E of M4 also appeared to be affected by the
mutation introduced (Fig. 6B); likely to be caused by a change of
local conformation, rather than a drop of expression level since
prM-binding by m2H2 was normal. Notably, the binding of D29
Fab-IgG to the E protein of the M3, M5 and M6 mutants were
severely affected; in particular, D29 Fab-IgG failed to detect E of
M4 and M5/6, whereas binding of prM for all these mutants was
not affected at all (Fig. 6B). Together these results confirm the
epitopes identified through peptide-phage display.
Antibody-dependent Neutralization and Enhancement
Previous studies with anti-prM antibodies have shown that
while the antibodies are generally non-neutralizing [9,25], they are
capable of rendering non-infectious immature DENV (imDENV)
particles infectious through an FccR-mediated process [9,12].
Indeed, D29 Fab-IgG failed to neutralize any of the 4 serotypes of
DENV at the highest concentration tested (400 mg/ml) in a PRNT
assay (Table S1). Next, the ability of D29 Fab-IgG to enhance
infection of DENV2 and imDENV2 was determined by carrying
out ADE assays with FccR-bearing K562 cells. The specific
infectivity of the viruses was established by qPCR and plaque assay
to be 8.5610
5:1 for imDENV2, which was significantly higher
than that of the standard-grown DENV2 at 240:1 (Fig. 7A).
Enhancement of DENV2 infection was observed for all
antibodies, with the exception of the non-DENV specific antibody.
All the DENV-specific antibodies caused an approximately 20-fold
increase in infection compared with IgG control (Fig 7B). As D29
Fab-IgG is non-neutralizing, it was capable of enhancing infection
of prM-containing virus in the preparation for the entire range of
concentrations tested.
Infection of virtually non-infectious imDENV was also signif-
icantly enhanced by D29 Fab-IgG to a level similar to m2H2,
causing an 80–100 fold increase in infection relative to control IgG
(Fig. 7C). The enhancement of imDENV infection by h3H5 was
similar to that observed for DENV2, since its epitope was not
affected by the maturity state hence it enhanced both equally well;
h4G2 failed to enhance imDENV2 infection in K562 cells possibly
be due to the occlusion of its epitope by the pr peptide [29,30], and
indicated by the immunoprecipitation protein profile (Fig. 3B).
Discussion
To gain a deeper understanding of the early immune response
against DENV, we have isolated and characterised a highly cross-
reactive antibody fragment – D29, from a non-immune human
Fab-phage library that shows near germline sequence. Upon
conversion into full-length IgG, D29 showed cross-reactivity
against all four serotypes of DENV and could be competed with
the prM-specific mouse antibody 2H2. Intriguingly, D29 Fab-IgG
was found to recognize both E and prM during Western blot
analysis in a conformational dependant manner. Cross-reactivity
between E and prM has been observed in antibodies isolated from
mice as well as human patients [10,11,21]. However, the binding
epitopes of these antibodies remain unknown and the observation
is usually explained by general cross-reactivity of anti-prM
antibodies.
Initial immunoprecipitation experiments with D29 Fab-IgG
precipitated both prM and E proteins. However, upon dissociation
of the prM interaction with E by the addition of SDS, only prM
was precipitated by D29 Fab-IgG, pinpointing prM as the native
binding target. Similarly, h3H5 only precipitated E upon addition
of SDS, whereas the protein profile precipitated by h4G2 was not
affected possibly due to its epitope at the fusion loop of E being
Figure 6. Site-directed mutagenesis of predicted epitope on
prM-E protein. (A) To confirm the binding epitope of D29 Fab-IgG,
residues within the P3 and P9 predicted sequences were mutated to
generate mutants 1–6 (M1-6); M3/4, M3/5, M4/5 and M5/6 contain
combinational-mutations as stated. (B) Reactivity of antibodies with the
mutants was tested by Western blot analysis. Cleared lysate of DENV2-
infected Vero cells (DV2), pCMV-prM-E- (prM-E) or mutants-transfected
HEK 293 T cells (M1-5/6) were separated on 12% SDS-PAGE in non-
reducing condition, followed by detection with h4G2, m2H2 and D29
Fab-IgG.
doi:10.1371/journal.pone.0033451.g006
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proteins were pulled down in both the presence and absence of
SDS.
The epitope of D29 was mapped using a random-peptide
phage display library, an approach which has been widely used
for the identification of both linear and conformational epitopes
[26,31–34]. Two peptide phage clones, P3 (Cluster 1) and P9
(Cluster 2), displayed significant inhibition of D29 Fab-IgG
binding to immobilized DENV2 by ELISA; P9 was also able to
significantly block the binding of D29 Fab-IgG in a non-
reducing Western blot analysis. This may be due to a better
sequence match of P9 to its predicted cluster compared with P3
(Fig. 5), hence, a higher affinity of the peptide to D29 Fab-IgG.
To ascertain the authenticity of the predicted epitopes, the
predicted residues were confirmedb ys i t e - d i r e c t e dm u t a g e n e s i s
of the P3 and P9 peptide sequence. The residues P56L, P58Q
and P59N within the P3 epitope weref o u n dt ob et h ep r i n c i p l e
residues involved in the interaction between prM and D29 Fab-
IgG; they were also critical for the binding of m2H2,
corroborating with results of competition assays. The binding
for E protein was not really affected by mutation of aa residues
within the P3 epitope; contrasting to the significant impact
caused by mutation of 1–2 residues within the P9 epitope. The
combined mutation of E129V, E131Q, E133E, and E134N
completely abolished binding of D29 Fab-IgG to E protein,
establishing the critical residues within the P9 epiotpe. Taken
together, these results suggest that D29 Fab-IgG recognises two
epitopes on DENV – a solvent-accessible epitope on prM as the
principle binding epitope, and a cryptic epitope on E which
mimics the prM epitope but is not available on a native,
functionally-folded E protein. The P3 and P9 epitopes are
highly conserved across the four DENV serotypes, as well as two
other flaviviruses, Japanese encephalitis virus and West nile
virus; but with increasing divergence in Yellow fever virus and
Tick-borne encephalitis virus (Fig. S4).
Most current dengue vaccines consist of both prM and E
proteins [12,13,35]; studies performed with tick-borne encephalitis
virus indicate that proper folding of E requires the chaperone
function of prM [36]. However, as demonstrated in this study and
recent reports, prM-specific antibodies are able to restore and
enhance the infectivity of imDENV and partially mature DENV
[9,11,12]; it may be worthwhile to consider alternative vaccine
approaches that minimize anti-prM responses during vaccine
design [9]. The findings from our study also suggest that any
partial denaturation or unfolding of an E protein vaccine
preparation may result in the exposure of a cryptic P9-like
epitope, which has the potential to induce D29-like antibodies with
threatening ADE capability.
A recent study investigating the acute and early convalescent B
cell response in dengue patients has found dengue virus to have a
significant B cell activation capacity, causing a transient but high
appearance of plasmablast and plasma cell, coinciding with that of
dengue-specific IgG antibodies at day 4–7 after onset of fever [37].
The similarity of D29 Fab-IgG to germline sequence suggests that
such antibodies are present in the immune repertoire of naı ¨ve
individuals and given the inherent high affinity of D29, such
antibodies may be preferentially selected during clonal expansion
and maintained as memory. Indeed, antibodies that cross-react
between prM and E has been isolated from memory B cells in
primary and secondary dengue patients [9,11]. The original
immunogens for these cross-reactive antibodies are difficult to
determine since they were generated in the course of natural
infections, but it would be interesting to identify the epitope and
germline of these antibodies and compare the sequences with D29
Fab-IgG.
Supporting Information
Figure S1 Binding enrichment of Fab phage and SDS-
PAGE analysis of D29 Fab-IgG. (A) Purified DENV2 was
coated on Maxisorb plate and polyclonal phage after each round
of panning was added at 1:10 v/v dilution along with unpanned
phage as control. Bound phages were detected with HRP-
conjugated anti-M13 monoclonal antibody. (B) D29 was converted
into human IgG format and expressed in HEK 293 T cells. The
quality of resulting IgG was analysed by resolving 2.5 mgo f
antibody on 12% SDS-PAGE with (lane 1) or without (lane 2) the
presence of DTT.
(TIF)
Figure S2 Alignment of D29 Fab-IgG with germline
sequence. The amino acid sequence of D29 IgG was aligned
with the germline sequence using the on-line program IgBlast.
CDR - (complementarity determining region); HC – antibody
heavy chain; LC - antibody light chain.
(TIF)
Figure S3 Epitope mapping using synthetic linear
peptides. In attempt to identify D29 Fab-IgG’s target on E
Figure 7. Effect of DENV maturation state on ADE profile by D29 Fab-IgG. (A) The specific infectivity of DENV2 and imDENV2 was
determined. Serially diluted anti-DENV antibodies were incubated with (B) DENV2 or (C) imDENV2 at MOG 25 for 1 hr at 37
oC before infection of
2610
4 K562 cells for 2 days. Viral titer was quantified by plaque assay (limit of detection is 0.5610
2 pfu/ml). Data presented is the average of three
independent experiments with error bars representing the standard deviation.
doi:10.1371/journal.pone.0033451.g007
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(A) and E (B) was incubated with D29 Fab-IgG. Peptides
corresponding to E were tested individually but presented as
groups of 5. For all experiments, 2610
6 pfu/ml of DENV2 or
imDENV2 was included as control antigen. M1-32: 15 mer
peptides corresponding to prM. Pr1-5: .20 mer custom-made
peptides covering parts of prM. E1-73: 15 mer peptides corre-
sponding to E. (**p-value,0.005)
(TIF)
Figure S4 Alignment of residues corresponding to the
D29 epitopes. Residues of flaviviruses (from top to bottom –
DENV1 Hawaii, DENV2 16881, DENV3 H87, DENV4 H241,
Japanese encephalitis virus (JEV) P3, West Nile virus (WNV)
NY2003suffolk, Yellow fever virus (YV) 17D204USA, Tick-borne
encephalitis virus (TBEV) western subtype vaccine strain Neu-
doerfl) corresponding to P3 and P9 epitopes are aligned. Residues
identical to the predicted sequence are depicted as dots.
(TIF)
Materials and Methods S1
(DOC)
Table S1 PRNT50 value of DENV-specific antibodies.
(DOCX)
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